de Wit R - Search Results

1

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.

Bellmunt J, de Wit R, Albanell J, Baselga J. Bellmunt J, et al. Among authors: de wit r. Eur J Cancer. 2001 Nov;37(17):2212-5. doi: 10.1016/s0959-8049(01)00295-7. Eur J Cancer. 2001. PMID: 11677109 Clinical Trial.

2

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.

de Wit R, Tesselaar M, Kok TC, Seynaeve C, Rodenburg CJ, Verweij J, Helle PA, Stoter G. de Wit R, et al. Eur J Cancer. 1991;27(11):1383-5. doi: 10.1016/0277-5379(91)90015-6. Eur J Cancer. 1991. PMID: 1835851 Clinical Trial.

3

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors.

de Wit R, Pawinsky A, Stoter G, van Oosterom AT, Fosså SD, Paridaens R, Svedberg A, de Mulder PH. de Wit R, et al. Among authors: de mulder ph. Eur J Cancer. 1997 Mar;33(3):493-5. doi: 10.1016/s0959-8049(97)89027-2. Eur J Cancer. 1997. PMID: 9155537 Clinical Trial.

4

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma.

Pawinski A, van Oosterom AT, de Wit R, Fosså S, Croles J, Svedberg A, Lentz MA, de Mulder PH. Pawinski A, et al. Among authors: de wit r, de mulder ph. Eur J Cancer. 1997 Mar;33(3):496-9. doi: 10.1016/s0959-8049(97)89028-4. Eur J Cancer. 1997. PMID: 9155538 Clinical Trial.

5

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Borner MM, et al. Among authors: de wit r, de boer rf. Eur J Cancer. 2002 Feb;38(3):349-58. doi: 10.1016/s0959-8049(01)00371-9. Eur J Cancer. 2002. PMID: 11818199 Clinical Trial.

6

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.

van den Bent MJ, van Putten WL, Hilkens PH, de Wit R, van der Burg ME. van den Bent MJ, et al. Among authors: de wit r. Eur J Cancer. 2002 Feb;38(3):387-91. doi: 10.1016/s0959-8049(01)00381-1. Eur J Cancer. 2002. PMID: 11818204

7

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.

Louwerens M, Smorenburg C, Sparreboom A, Loos WJ, Verweij J, de Wit R. Louwerens M, et al. Among authors: de wit r. Eur J Cancer. 2002 Mar;38(4):497-504. doi: 10.1016/s0959-8049(01)00386-0. Eur J Cancer. 2002. PMID: 11872341 Clinical Trial.

8

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

de Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, van der Burg ME. de Jongh FE, et al. Among authors: de wit r. Eur J Cancer. 2002 Oct;38(15):2005-13. doi: 10.1016/s0959-8049(02)00242-3. Eur J Cancer. 2002. PMID: 12376205 Clinical Trial.

9

Overview of gemcitabine triplets in metastatic bladder cancer.

de Wit R, Bellmunt J. de Wit R, et al. Crit Rev Oncol Hematol. 2003 Feb;45(2):191-7. doi: 10.1016/s1040-8428(02)00079-3. Crit Rev Oncol Hematol. 2003. PMID: 12604129 Review.

10

New drugs and new approaches in metastatic bladder cancer.

Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J. Bellmunt J, et al. Among authors: de wit r. Crit Rev Oncol Hematol. 2003 Aug;47(2):195-206. doi: 10.1016/s1040-8428(03)00082-9. Crit Rev Oncol Hematol. 2003. PMID: 12900012 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page